drugset / Trial / NCT06456580

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580

Phase 3 Recruiting 180 enrolled Vor Biopharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Timeline

Start
2024-07-17
Primary completion
2027-05
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Telitacicept Protein / enzyme biologic Subcutaneous